Amgen Inc. (NASDAQ:AMGN) Shares Purchased by National Pension Service

National Pension Service increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 897,035 shares of the medical research company’s stock after purchasing an additional 17,831 shares during the quarter. National Pension Service owned approximately 0.17% of Amgen worth $258,364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in Amgen in the third quarter valued at approximately $26,000. Briaud Financial Planning Inc purchased a new stake in shares of Amgen during the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. acquired a new position in Amgen during the 4th quarter worth approximately $29,000. Providence Capital Advisors LLC purchased a new position in Amgen in the 3rd quarter worth approximately $30,000. Finally, Planned Solutions Inc. purchased a new stake in Amgen during the 4th quarter worth $30,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is currently owned by corporate insiders.

Amgen Stock Up 1.7 %

Shares of AMGN stock traded up $5.14 on Thursday, reaching $312.45. 838,264 shares of the company’s stock traded hands, compared to its average volume of 2,885,828. The company has a market capitalization of $167.61 billion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The business’s 50 day moving average price is $275.65 and its two-hundred day moving average price is $281.74.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.98 earnings per share. On average, equities analysts forecast that Amgen Inc. will post 19.46 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.88%. Amgen’s dividend payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Royal Bank of Canada decreased their price target on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. UBS Group upped their price target on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. TD Cowen lowered their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and boosted their price objective for the company from $230.00 to $300.00 in a research report on Friday, May 3rd. Finally, The Goldman Sachs Group raised their target price on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $305.65.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.